GEN Exclusives

More »

GEN News Highlights

More »
Jul 17, 2007

Organon and Dyax Ink Antibody Pact

  • Organon and Dyax will work together to discover and develop human therapeutic antibodies for the treatment of autoimmune diseases and cancer. Dyax will utilize its phage-display technology to find antibodies directed toward a target identified at Organon’s research center in Cambridge, MA.

    “It is our strategy to expand the portfolio of commercially attractive biotech products,” remarks David Nicholson, executive vp R&D of Organon. “Dyax’ state-of-the-art phage-display technology will help us to strengthen our R&D pipeline of antibody therapies for cancer and autoimmune disorders.”

    According to the terms of the collaboration, Dyax will receive license fees and research funding as well as milestone payments and royalties.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?